Healthcare entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Food and Drug Administration, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 5.9.
Last mentioned: Mar 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Food and Drug Administration, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 5.9. Each story carries 2 original sources on average, compared with 4.3 for the broader beat in this window. Vinay Prasad appears in 1 tracked Healthcare story from March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vinay Prasad. Shared-story counts are live from our verified record — not editorial picks.
Public Criticism
Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.
Refusal to File
Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.
Grants Rescinded
The administration pulls back hundreds of millions in funding for mRNA-based research projects.
Trial Design Support
FDA officials reportedly signal support for Moderna's flu vaccine trial workaround and data submission plan.
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the height of pandemic vaccine distribution.
The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response.
Vinay Prasad is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
